For example, a small molecule multi kinase inhibitor, sunitinib, has been permitted to treat metastatic renal cell carcinoma which degrade autophagic induction of wild type p53 proteins in a multiple cancer cell lines (Luo et al., 2018). Here, TP53 is linked to cancer.